Mereo BioPharma Group plc business relationships

Companies named in Mereo BioPharma Group plc’s 10-K filed 2026-03-19, and public companies whose annual reports name Mereo BioPharma Group plc. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 5.4 / 10
AI naming: 72 / 100
Agent readiness: 0 / 100
AI adoption: 0 / 100

Named in Mereo BioPharma Group plc’s annual report 9

ASTRAZENECA PLC (AZN)Licensor7.7
“License agreement with AstraZeneca” SEC filing
NOVARTIS AG (NVS)Licensor7.7
“Business-Material Agreements-Licensing Agreement with AstraZeneca," under various agreements with Novartis and AstraZeneca, Mereo has agreed to make milestone payments and pay royalties.” SEC filing
ASTRAZENECA PLC (AZN)Partner7.7
“We have strong relationships with these companies, as evidenced by our agreements with Novartis AG ("Novartis") and AstraZeneca AB ("AstraZeneca"), as well as our partnership with Ultragenyx, and a track record of structuring transactions that enable us to leverage our core capabilities while creati...” SEC filing
NOVARTIS AG (NVS)Partner7.7
“We have strong relationships with these companies, as evidenced by our agreements with Novartis AG ("Novartis") and AstraZeneca AB ("AstraZeneca"), as well as our partnership with Ultragenyx, and a track record of structuring transactions that enable us to leverage our core capabilities while creati...” SEC filing
REGENERON PHARMACEUTICALS, INC. (REGN)Partner7.7
“We expect Yoltech Therapeutics, Cornell University, AIRNA, Prime Medicine, CRISPR Therapeutics, and Tessera Therapeutics (a program that is partnered with Regeneron) each to begin early-stage clinical trials in AATD over the next 12-18 months.” SEC filing
ELI LILLY & Co (LLY)Licensee6.6
“In addition, Transcenta Holding has licensed the Chinese rights to the anti-sclerostin antibody blosozumab from Eli Lilly and Company ("Lilly") and plans to develop it for osteoporosis.” SEC filing
Ultragenyx Pharmaceutical Inc. (RARE)Licensor6.1
“First Amendment to Collaboration and License Agreement, dated May 20, 2025, between Mereo BioPharma 3 Limited and Ultragenyx Pharmaceutical Inc.” SEC filing
CRISPR Therapeutics AG (CRSP)Partner5.5
“We expect Yoltech Therapeutics, Cornell University, AIRNA, Prime Medicine, CRISPR Therapeutics, and Tessera Therapeutics (a program that is partnered with Regeneron) each to begin early-stage clinical trials in AATD over the next 12-18 months.” SEC filing
GSK plc (GSK)Partner5.5
“Wave has initiated a Phase 1/2 study of RNA base-editing oligonucleotide (WVE-0006) to restore wild-type protein in lung and liver disease, a program that has been partnered with GSK.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.